含阿扎胞苷及米托蒽醌脂质体化疗方案治疗血管免疫母细胞性T细胞淋巴瘤1例并文献复习

Chemotherapy regimens containing azacitidine and mitoxantrone liposome for angioimmunoblastic T-cell lymphoma:report of 1 case and review of literature

目的探讨含有阿扎胞苷及米托蒽醌脂质体化疗方案治疗血管免疫母细胞性T细胞淋巴瘤(AITL)患者的效果。方法回顾性分析威海市立医院2021年7月收治的1例临床症状严重AITL患者的临床资料,并进行相关文献复习。结果患者为74岁男性,以皮疹、淋巴结肿大、腹胀、发热就诊。经淋巴结活组织检查病理诊断为AITL,治疗前期因临床症状重、治疗效果不佳,不断调整治疗方案,先后给予CHOPE、依托泊苷+西达本胺+沙利度胺+地塞米松+环孢素、维布妥昔单抗+苯达莫司汀+地塞米松+环孢素+沙利度胺+西达本胺等方案治疗,患者获得短期完全缓解后出现疾病进展,最终采用含有阿扎胞苷及米托蒽醌脂质体的多药联合方案治疗,再次获完全缓解,后以阿扎胞苷联合西达本胺等方案维持治疗,监测病情持续稳定。结论对于难治复发AITL,采用含有阿扎胞苷及米托蒽醌脂质体的化疗方案治疗,可取得较好的治疗效果。

ObjectiveTo investigate the treatment outcome of chemotherapy regimens containing azacitidine and mitoxantrone liposome in the treatment of angioimmunoblastic T-cell lymphoma(AITL).MethodsThe clinical data of 1 AITL patient with severe clinical symptoms admitted to Weihai Municipal Hospital in July 2021 were retrospectively analyzed,and the relevant literatures were reviewed.ResultsThe 74-year-old male patient was presented with the manifestations of rash,lymph node enlargement,bloating and fever.He was pathologically diagnosed as AITL by lymph node biopsy.In the early stage of treatment,due to severe clinical symptoms and poor therapeutic effect,the treatment regimens were constantly adjusted.CHOPE,etoposide+chidamide+thalidomide+dexamethasone+cyclosporine,brentuximab vedotin+bendamustine+dexamethasone+cyclosporine+thalidomide+chidamide regimens were used successively,and the disease progressed after short-term complete remission.Finally complete remission was obtained again after a multi-drug combination regimens containing azacitidine and mitoxantrone liposome,following the maintenance treatment of azacitidine combined with chidamide,and the disease condition of the patient remained stable.ConclusionsThe chemotherapy regimens containing azacitidine and mitoxantrone liposome can achieve a good therapeutic effect for relapsed/refractory AITL.